BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1512 related articles for article (PubMed ID: 33246024)

  • 1. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
    Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
    Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nationwide cohort study comparing the effectiveness of diuretics and calcium channel blockers on top of renin-angiotensin system inhibitors on chronic kidney disease progression and mortality.
    Faucon AL; Fu EL; Stengel B; Mazhar F; Evans M; Carrero JJ
    Kidney Int; 2023 Sep; 104(3):542-551. PubMed ID: 37330214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kidney, Cardiac, and Safety Outcomes Associated With α-Blockers in Patients With CKD: A Population-Based Cohort Study.
    Hundemer GL; Knoll GA; Petrcich W; Hiremath S; Ruzicka M; Burns KD; Edwards C; Bugeja A; Rhodes E; Sood MM
    Am J Kidney Dis; 2021 Feb; 77(2):178-189.e1. PubMed ID: 32920153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study.
    Fu EL; Evans M; Clase CM; Tomlinson LA; van Diepen M; Dekker FW; Carrero JJ
    J Am Soc Nephrol; 2021 Feb; 32(2):424-435. PubMed ID: 33372009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
    Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
    Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
    Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
    Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of first-line antihypertensive drug classes on the maintenance of estimated glomerular filtration rate (eGFR) in real world primary care.
    Gao Q; Tan NC; Lee ML; Hsu W; Choo J
    Sci Rep; 2023 Dec; 13(1):21225. PubMed ID: 38040765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CKD Progression and Mortality Among Men and Women: A Nationwide Study in Sweden.
    Swartling O; Rydell H; Stendahl M; Segelmark M; Trolle Lagerros Y; Evans M
    Am J Kidney Dis; 2021 Aug; 78(2):190-199.e1. PubMed ID: 33434591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
    Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
    J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study.
    Schroeder EB; Chonchol M; Shetterly SM; Powers JD; Adams JL; Schmittdiel JA; Nichols GA; O'Connor PJ; Steiner JF
    Clin J Am Soc Nephrol; 2018 May; 13(5):727-734. PubMed ID: 29572286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
    Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
    PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes between calcium channel blockers and angiotensin receptor blockers in hypertensive patients without established cardiovascular diseases during a 3-year follow-up.
    Jeong HS; Lim HS; Park HJ; Lee WS; Choi JO; Lee HS; Jo SH; Hong SJ
    Sci Rep; 2021 Jan; 11(1):1783. PubMed ID: 33469103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
    Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
    Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
    J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-Angiotensin-Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries.
    Htoo PT; Stürmer T; Jonsson-Funk M; Pate V; Simpson RJ; Lund JL
    Epidemiology; 2019 Nov; 30(6):867-875. PubMed ID: 31348009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.